ALC vs TAK
Alcon Inc vs Takeda Pharmaceutical Company Limited — AI-powered side-by-side comparison
VS
TAK
Takeda Pharmaceutical Company Limited
67
Insufficient Data
| Metric | ALC | TAK |
|---|
| AI Score |
68
|
67
|
| Price |
$75.39
|
$17.49
|
| P/E Ratio |
45.39×
|
48.87×
|
| ROE |
4.4%
|
2.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
54.9%
|
62.1%
|
| Debt / Equity |
0.24×
|
0.65×
|
| Dividend Yield |
0.5%
|
3.6%
|
| RSI (14) |
73.4
|
61.6
|
| Beta |
0.703
|
0.088
|
| Expected Upside |
+11.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALC versus TAK.
ALC leads by 1 points.
ALC scores 68/100 (Buy) versus TAK at 67/100 (Insufficient Data).
ALC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 73 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 73 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
TAK Committee View
67% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical